Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

It has been nearly a year since my last Sarepta Therapeutics (NASDAQ:SRPT) article, when the ticker was trading near $160 per share. At that time, Sarepta was riding high on the FDA’s landmark expanded approval of Thank you for reading my research on Seeking Alpha. If you want to learn even more…